Bridging the Gap Between Basic Research and Industrial Application
Professor Dr Pierre Jacobs, KU Leuven (Belgium), has received the BASF-DECHEMA Alwin Mittasch Special Prize for his research into materials and their use as process catalysts. The award, which comes with €10,000 in prize money, was presented at the “Future Loves History — 100 Years of Ammonia Synthesis” scientific symposium at BASF in Ludwigshafen.
“Professor Jacobs has succeeded in a special way in spanning the bridge between basic research and industrial application,” said Professor Rainer Diercks, President Petrochemicals BASF and Chairman of DECHEMA. Initially focusing on zeolites and their use in catalysis, Pierre Jacobs gradually expanded his research activities to include other heterogeneous and homogeneous catalytic processes. Many of his research insights are now in industrial use. These include synthesis of g-butyrolactone from maleic acid anhydride, an important step in the manufacture of anti-dementia drugs, and side chain alkylation of alkyl-substituted anthraquinones, an intermediate step in industrial hydrogen peroxide production. His research areas also include catalytic processing of biomass.
DECHEMA confers the Alwin Mittasch Prize usually every 3 years. This year BASF sponsored a special prize to mark the 100th anniversary of the commissioning of the first ammonia plant in September 1913. “Without the enormous efforts of catalyst research, the Haber-Bosch process for ammonia production would never have been transferred to industrial scale and this world would be a different place,” Dr Peter Schuhmacher, President Process Research and Chemical Engineering said. “For that reason, it was a matter of great importance to us to present the award to someone who is continuing Alwin Mittasch’s legacy.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance